2. Academic Validation
  3. TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro

TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro

  • Antimicrob Agents Chemother. 2005 Aug;49(8):3483-5. doi: 10.1128/AAC.49.8.3483-3485.2005.
Cécile L Tremblay 1,  Françoise Giguel,  Yongbiao Guan,  Ting-Chao Chou,  Katsunori Takashima,  Martin S Hirsch
Affiliations

Affiliation

  • 1 Massachusetts General Hospital, 65 Landsdowne St., Room 419, Cambridge, MA 02139, USA. mshirsch@partners.org
PMID: 16048964 DOI: 10.1128/AAC.49.8.3483-3485.2005
Abstract

TAK-220 is a CCR5 Antagonist, part of the new class of anti-human immunodeficiency virus type 1 (anti-HIV-1) entry inhibitors. We evaluated the anti-HIV-1 interactions between TAK-220 and various antiretrovirals in vitro. Synergy was observed with all drugs at the 90 and 95% inhibitory concentrations. The favorable drug interactions observed suggest that further clinical evaluation is warranted.

Figures
Products